Drug Trial Radar · NCT04746911
Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)
Last checked: Nov 20, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Mar 1, 2021
Primary completion
May 11, 2022
Study completion May 11, 2022
Sponsor
- Lead sponsor
- Arcutis Biotherapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 5 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, open label, maximal usage PK and safety study of ARQ-151 cream 0.3% in pediatric subjects (ages 2 to 5 years old) with plaque psoriasis:
Conditions
- Psoriasis
- Plaque Psoriasis
Interventions
ARQ-151 cream 0.3%Drug
ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma Concentration of Roflumilast Following Daily Application of Roflumilast Cream 0.3%Time frame: Weeks 2 and 4: 1 hour predose
- Plasma Concentration of Major N-oxide Metabolite Following Daily Application of Roflumilast Cream 0.3%Time frame: Weeks 2 and 4: 1 hour predose
- Number of Participants With an Adverse Event (AE)Time frame: Up to 4 weeks
- Number of Participants With Application Site ReactionsTime frame: Up to 4 weeks
Locations
18 sites in 3 countries. Site status is shown where the registry gives one.
Arcutis Clinical Site 603
Mountain Brook, Alabama
Arcutis Clinical Site 604
Scottsdale, Arizona
Arcutis Clinical Site 609
Fountain Valley, California
Arcutis Clinical Site 618
Los Angeles, California
Arcutis Clinical Site 608
Los Angeles, California
Arcutis Clinical Site 611
Rancho Santa Margarita, California
Arcutis Clinical Site 610
Boca Raton, Florida
Arcutis Clinical Site 602
Coral Gables, Florida
Arcutis Clinical Site 613
Delray Beach, Florida
Arcutis Clinical Study Site 628
Miami, Florida
Arcutis Clinical Site 607
Miami, Florida
Arcutis Clinical Site 627
West Lafayette, Indiana
Arcutis Clinical Site 606
Arlington, Texas
Arcutis Clinical Site 619
Frisco, Texas
Arcutis Clinical Study Site 619
Frisco, Texas
Arcutis Clinical Site 605
Houston, Texas
Arcutis Clinical Site 621
Toronto, Ontario, Canada
Arcutis Clinical Site 630
Santo Domingo, Dominican Republic
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.